While its significance went relatively unnoticed in the UK media, it generated controversial headlines elsewhere in the world. However its results will undoubtedly influence future clinical practice guidelines.

All clinicians need to be part of the solution if we are to reduce the burden of overdiagnosis.

Thoughts and local perspective on applying the latest ABN guidance on DMTs use in MS